MedMesh.i
Checkpoint
PubMed
Racine
Checkpoint
PubMed
Exploration
Accueil
Racine
Racine

Serveur d'exploration Tocilizumab - Checkpoint (PubMed)

Index « MedMesh.i » - entrée « Matrix Metalloproteinase 3 »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Matrix Metalloproteinase 2 < Matrix Metalloproteinase 3 < Matrix Metalloproteinase 9  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 17.
Ident.Authors (with country if any)Title
000797 (2018) Kazuha Kizaki [Japon] ; Fumiharu Yamashita [Japon] ; Tomoya Hayashi [Japon] ; Noboru Funakoshi [Japon]Infliximab equivalently suppresses oxidative stress compared to tocilizumab among well-controlled patients with rheumatoid arthritis.
000809 (2018) Andrea D. Gloor [Suisse] ; Daniel Yerly [Suisse] ; Sabine Adler [Suisse] ; Stephan Reichenbach [Suisse] ; Stefan Kuchen [Suisse] ; Michael Seitz [Suisse] ; Peter M. Villiger [Suisse]Immuno-monitoring reveals an extended subclinical disease activity in tocilizumab-treated giant cell arteritis.
000A29 (2017) Shoichi Kaneshiro [Japon] ; Kosuke Ebina [Japon] ; Makoto Hirao [Japon] ; Hideki Tsuboi [Japon] ; Masataka Nishikawa [Japon] ; Akihide Nampei [Japon] ; Yoshio Nagayama [Japon] ; Koichiro Takahi ; Takaaki Noguchi [Japon] ; Hajime Owaki [Japon] ; Jun Hashimoto [Japon] ; Hideki Yoshikawa [Japon]The efficacy and safety of additional administration of tacrolimus in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab.
000C57 (2016) A S Avdeeva ; E N Aleksandrova ; D E Karateev ; E Yu Panasyuk ; A V Smirnov ; M V Cherkasova ; E L Nasonov[Relationship between matrix metalloproteinase-3 levels and articular destructive changes in early and extended rheumatoid arthritis].
000D49 (2016) Atsuko Murota [Japon] ; Katsuya Suzuki [Japon] ; Yoshiaki Kassai [Japon] ; Takahiro Miyazaki [Japon] ; Rimpei Morita [Japon] ; Yasushi Kondo [Japon] ; Masaru Takeshita [Japon] ; Yasuo Niki [Japon] ; Akihiko Yoshimura [Japon] ; Tsutomu Takeuchi [Japon]Serum proteomic analysis identifies interleukin 16 as a biomarker for clinical response during early treatment of rheumatoid arthritis.
001380 (2014) Norihiro Nishimoto [Japon] ; Koichi Amano ; Yasuhiko Hirabayashi ; Takahiko Horiuchi ; Tomonori Ishii ; Mitsuhiro Iwahashi ; Masahiro Iwamoto ; Hitoshi Kohsaka ; Masakazu Kondo ; Tsukasa Matsubara ; Toshihide Mimura ; Hisaaki Miyahara ; Shuji Ohta ; Yukihiko Saeki ; Kazuyoshi Saito ; Hajime Sano ; Kiyoshi Takasugi ; Tsutomu Takeuchi ; Shigeto Tohma ; Tomomi Tsuru ; Yukitaka Ueki ; Jiro Yamana ; Jun Hashimoto ; Takaji Matsutani ; Miho Murakami ; Nobuhiro TakagiDrug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study.
001415 (2014) Tetsuo Kobayashi [Japon] ; Moe Okada ; Satoshi Ito ; Daisuke Kobayashi ; Kohei Ishida ; Anri Kojima ; Ichiei Narita ; Akira Murasawa ; Hiromasa YoshieAssessment of interleukin-6 receptor inhibition therapy on periodontal condition in patients with rheumatoid arthritis and chronic periodontitis.
001444 (2013) A S Avdeeva ; E N Aleksandrova ; A A Novikov ; M V Cherkasova ; E Yu Panasyuk ; E L Nasonov[Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis].
001765 (2012) Morten A. Karsdal [Danemark] ; Georg Schett ; Paul Emery ; Olivier Harari ; Inger Byrjalsen ; Andy Kenwright ; Anne C. Bay-Jensen ; Adam PlattIL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522).
001790 (2012) Takao Nagashima ; Hitoaki Okazaki ; Yasuyuki Kamata ; Seiji MinotaComment on "Comparison of MMP-3 levels in rheumatoid arthritis after treatment with tocilizumab or infliximab for 12 weeks" by Yokoe et al.
001792 (2012) Atsushi Kaneko [Japon] ; Daihei Kida ; Kiwamu Saito ; Masami Tsukamoto ; Tomotaro SatoClinical results for tocilizumab over one year in the clinical setting as assessed by CDAI (clinical disease activity index): CRP at week 12 and MMP-3 at week 24 are predictive factors for CDAI.
001895 (2011) Katsuaki Kanbe [Japon] ; Qian Chen ; Atsushi Nakamura ; Kaori HoboInhibition of MAP kinase in synovium by treatment with tocilizumab in rheumatoid arthritis.
001927 (2011) Isamu Yokoe [Japon] ; Shinya Nishio ; Hiroshi Sato ; Hitomi KobayashiComparison of MMP-3 levels in rheumatoid arthritis after treatment with tocilizumab or infliximab for 12 weeks.
001996 (2010) Shin-Ya Kawashiri [Japon] ; Atsushi Kawakami ; Naoki Iwamoto ; Keita Fujikawa ; Toshiyuki Aramaki ; Mami Tamai ; Kazuhiko Arima ; Kunihiro Ichinose ; Makoto Kamachi ; Satoshi Yamasaki ; Hideki Nakamura ; Tomoki Origuchi ; Hiroaki Ida ; Katsumi EguchiSwitching to the anti-interleukin-6 receptor antibody tocilizumab in rheumatoid arthritis patients refractory to antitumor necrosis factor biologics.
001A07 (2010) Patrick Garnero [France] ; Elizabeth Thompson ; Thasia Woodworth ; Josef S. SmolenRapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone.
001B08 (2009) Keiko Funahashi [Japon] ; Satoru Koyano ; Takako Miura ; Takafumi Hagiwara ; Kosuke Okuda ; Tsukasa MatsubaraEfficacy of tocilizumab and evaluation of clinical remission as determined by CDAI and MMP-3 level.
001C82 (????) Anne Sofie Siebuhr [Danemark] ; Cecilie F. Kjelgaard-Petersen [Danemark] ; Shu Sun [Danemark] ; Inger Byrjalsen [Danemark] ; Claus Christiansen [Danemark] ; Morten Asser Karsdal [Danemark] ; Anne-Christine Bay-Jensen [Danemark]Suppression of active, but not total MMP-3, is associated with treatment response in a phase III clinical study of rheumatoid arthritis.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/PubMed/Checkpoint

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/MedMesh.i -k "Matrix Metalloproteinase 3" 

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/MedMesh.i  \
                -Sk "Matrix Metalloproteinase 3" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    indexItem
   |index=    MedMesh.i
   |clé=    Matrix Metalloproteinase 3
}}
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021